anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Several studies have reported a potential association between the gut microbiota (GM) and scoliosis. However, the causal relationship between GM and scoliosis and the role of inflammatory factors (IFs) as mediators remain unclear. This study aimed to analyze the relationship between GM, IFs, and scoliosis. We investigated whether IFs act as mediators in pathways from the GM to scoliosis. Additionally, using reverse Mendelian randomization (MR) analysis, we further investigated the potential impact of genetic predisposition to scoliosis on the GM and IFs. In this study, we searched for publicly available genome-wide association study aggregate data and utilized the MR method to establish bidirectional causal relationships among 211 GM taxa, 91 IFs, and scoliosis. To ensure the reliability of our research findings, we employed 5 MR methods, with the inverse variance weighting approach serving as the primary statistical method, and assessed the robustness of the results through various sensitivity analyses. Additionally, we investigated whether IFs mediate pathways from GM to scoliosis. Three negative causal correlations were observed between the genetic predisposition to GM and scoliosis. Additionally, both positive and negative correlations were found between IFs and scoliosis, with 3 positive and 3 negative correlations observed. IFs do not appear to act as mediators in the pathway from GM to scoliosis. In conclusion, this study demonstrated a causal association between the GM, IFs, and scoliosis, indicating that IFs are not mediators in the pathway from the GM to scoliosis. These findings offer new insights into prevention and treatment strategies for scoliosis.
The patients in the topical agent group were prescribed by the orthopedist. they will use the topical agent. Diclofenac in gel form was chosen as a topical agent in the light of the literature. In this context, patients in both groups will apply the topical agent around the knee joint 4 days a week, 2 times a day (every 12 hours) in the morning and evening for 6 weeks.
Participants from 1 to 17 years of age with nMPS II. Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted. Part 6 will also include a single collection of CSF.
Participants in the Usual Care group will not take part in an 6-month exercise intervention. They will continue to seek regular care from their primary care providers and attend six study visits.
The aim of this study was to estimate across-country genetic correlations for calving traits (birth weight, calving ease) in the Limousine breed. Correlations were estimated for eight populations (Czech Republic, joint population of Denmark, Finland, and Sweden, France, Great Britain, Ireland, Slovenia, Switzerland, and Estonia). An animal model on raw performance accounting for across-country interactions (AMACI) was used. (Co)variance components were estimated for pairwise combinations of countries. Fixed and random effects were defined by each country according to its national genetic evaluation system. The average across-country genetic correlation for the direct genetic effect was 0.85 for birth weight (0.69-0.96) and 0.75 for calving ease (0.62-0.94). The average correlation for the maternal genetic effect was 0.57 for birth weight and 0.61 for calving ease. After the estimation of genetic parameters, the weighted bending procedure was used to compute the full Interbeef genetic correlation matrix. After bending, direct genetic correlations ranged from 0.62 to 0.84 (with an average of 0.73) for birth weight and from 0.58 to 0.82 (with an average of 0.68) for calving ease.
Therapeutic index (TI) is a measure of drug safety based on the differential between minimal effective dose and maximal tolerable dose. Many small-molecule drugs show limited TI (below 10). Given patient variability, such a limited range can become further narrowed for a drug in practice, complicating its real-world use. Epigenetic drugs such as nuclear receptor ligands (NRLs)—which must reach the target cell's nucleus in order to function—pose a particular challenge because small-molecule drugs typically lack the evolved biological “intelligence” that natural molecules employ in order to reach their intracellular targets efficiently. Methods and compositions are disclosed herein for the treatment of peripheral immune tissues (PIT) using NRLs covalently attached to immodulin peptides. PIT includes surface draining lymph nodes of the upper and lower limbs and adjacent skin tissues. Dramatic improvements in the TI of NRLs can be gained from the immodulin scaffold's anatomic specificity (natural homing to PIT), precise organelle targeting (efficient cellular uptake and nuclear transport), and tunable mechanism of transcriptional action (immodulins themselves drive intranuclear RXR heterodimer formation naturally, thereby placing NRLs in close proximity to their RXR-heterodimer targets). The combined effect of such improvements is a 2-100-fold improvement in functional TI for small-molecule NRL drugs. This invention discloses three key components of that observed improvement: a preferential anatomical distribution of immodulins to the peripheral immune system when administered via a transdermal route, addition of hyaluronic acid to the diluent to enhance homing, and the novel use of transferrin for enhancing NRL-liganded immodulin recovery from a polymer-protected transdermal formulation.
PURPOSE: To obtain confectionery that dissolves in the mouth and is excellent in taste by incorporating a volatile oil and such an amt. of a masking agent mildly controlling the volatile oil and reducing bitter as to improve the sensory characteristics of the volatile oil when it is released in the mouth. CONSTITUTION: A volatile oil such as menthol and a masking agent mildly controlling the volatile oil and reducing bitter selected from among fenchone, borneol and isoborneol are incorporated into confectionery. The amt. of the masking agent is regulated to such a degree that the masking agent is not sensitively detectable in the mouth but can improve the sensory characteristics of the volatile oil when it is released in the mouth. The pref. amt. is 0.5-50ppm based on the weight of the confectionery.
An aqueous post-foaming composition comprising (i) 2-20% wt of anionic surfactant(s), (ii) 1-10% wt of amine oxide surfactant(s), (iii) 0.5-3% wt of a hydrophobically modified alkali-swellable acrylic emulsion (HASE) polymer, as polymer solids, (iv) 1-50% wt of an oil and (v) a foaming agent comprising a non-polar saturated aliphatic hydrocarbon having 3-6 carbon atoms. The HASE polymer may be an acrylate/steareth-20 methacrylate crosspolymer, an acrylate/beheneth-25 methacrylate copolymer or an acrylate/palmeth-25 acrylate copolymer, preferably at an amount of 1-2% by weight. A preferred anionic surfactant is sodium laureth sulphate (SLES). Preferred amine oxide surfactants are lauramine oxide, myristamine oxide, cocamine oxide, lauramidopropyl amine oxide, myristamidopropyl amine oxide and cocamidopropyl amine oxide, at an amount of 1-5% wt. The foaming agent may be n-butane, isobutane, n-pentane, isopentane or neopentane, at an amount of 2-20% wt. A preferred amount of oil is also 2-20% wt. The composition may further comprise several other ingredients. It is in gel or cream form and it may be used as a body, facial or hand wash, for washing hair or as a shaving gel, producing creamy foam in use. It may also serve as a vehicle for the delivery of various ingredients to the skin or hair.
Neoadjuvant Toripalimab 240 mg IV on cycle 1 day 1 (C1D1), C2D1 and C3D1 before radical surgery for lung cancer. The participants will attend follow-up visits based on molecular residual disease (MRD) and receive adjuvant treatment including EGFR-TKI or chemotherapy if recommended.
Diclofenac Sodium Topical Gel, 1% is a nonsteroidal anti-inflammatory drug (NSAID) for topical use only. The chemical name is 2-[(2,6-dichlorophenyl) amino]benzene-acetic acid, monosodium salt. The molecular weight is 318.14. Its molecular formula is C14H10Cl2NNaO2, and it has the following chemical structure:

It contains the active ingredient, diclofenac sodium, in an opaque, white gel base. Diclofenac sodium is a white to slightly yellow crystalline powder. Diclofenac sodium is a benzeneacetic acid derivative.

The inactive ingredients in Diclofenac Sodium Topical Gel include: carbomer homopolymer Type C, cocoyl caprylocaprate, fragrance, isopropyl alcohol, mineral oil, polyoxyl 20 cetostearyl ether, propylene glycol, purified water, and strong ammonia solution.
Cannulation of the bile duct is a prerequisite to successful therapeutic biliary endoscopy. Cannulation itself can carry substantial risk to the patient. Acute pancreatitis following ERCP can occur up to 5% of cases. The risk increases in patients with non dilated bile ducts, young age, known past history of pancreatitis and suspected sphincter of oddi dysfunction. During the procedure of ERCP, the number of pancreatograms also correlates with incidence of post ERCP pancreatitis. Hydrostatic pressure by contrast injection into the pancreatic duct may be the principal cause of pancreatitis. We performed a meta-analysis of randomized controlled trials that compared the technique of contrast guided to wire guide cannulation in achieving bile duct cannulation during ERCP and found that wire guide cannulation was better at the prevention of post ERCP pancreatitis. The use of a guide wire obviates the need for contrast injection. The current standard is the use of a 0.035" guidewire with a hydrophilic tip. We now postulate that the use of a 0.025" further reduces post-ERCP pancreatitis as a finer wire theoretically induces less trauma to the pancreatic orifice.
The invention discloses a traditional Chinese medicine preparation for mainly treating constipation and a preparation method thereof. The traditional Chinese medicine preparation is composed of, by mass, 1-4 g of turtle oil, 10-15 g of edestan, 10-15 g of immature bitter oranges, 10-15 g of radix adenophorae and 10-15 g of radix ophiopogonis. The preparation method comprises the steps that turtle fat is refined into the turtle oil with a mild fire for standby application, and the temperature of the mild fire is 70-90 DEG C; edestan, immature bitter oranges, radix adenophorae and radix ophiopogonis are added in water of which the mass is 5-10 times of that of the four raw materials, the mixture is decocted for 2-4 h to obtained medicine juice, then the turtle oil is added in the medicine juice, and the traditional Chinese medicine preparation for mainly treating the constipation is obtained. The traditional Chinese medicine preparation has the advantages that the treating effect is good, the treating mode is simple and convenient, and side effects do not exist. When the traditional Chinese medicine preparation is taken, the turtle oil is added in the medicine juice, then the mixture is taken after being mixed with warm water, and the preparation is taken 2-3 times a day. The adopted traditional Chinese medicine components are convenient to acquire, a patient only needs to insist on continuously taking the preparation, and the cure rate is above 90 percent.
After explaining the study and obtaining written consent, a 3D ultrasound will be performed for uterine evaluation, on the day of the final oocyte maturation trigger in cases of IVF / ICSI. In cases of FET, the ultrasound evaluation will be carried out on the day before the start of the luteal phase support.

All ultrasounds will be performed in a standardized manner by the same operator. With an empty bladder, in a lithotomy position, a 2D transvaginal ultrasound will be performed using a GE Voluson 730 Expert® ultrasound, with an endovaginal probe with a 4-8MHz frequency. Identification of endometriosis lesions or acquired uterine abnormalities such as leiomyomas or adenomyosis will be exclusion criteria. After evaluating the number and maximum dimension of the ovarian follicles and the endometrial thickness, the three-dimensional volume box will be placed to encompass the entire uterus in longitudinal section, with minimal inclusion of para-uterine structures. A maximum acquisition angle of 90º and maximum quality will be used. To minimize artifacts, during the acquisition both the probe and the woman must remain immobile, being asked to hold their breath. Then, a three-dimensional volume will be generated by automatic 360º rotation of the transducer. For each case, two volumes will always be obtained.
PURPOSE: This study aimed to investigate the surgical outcomes of laparoscopic inguinal hernia repair using an Endoscope Manipulator Robot (EMARO).
METHODS: This retrospective study included 51 patients who underwent laparoscopic inguinal hernia repairs. The transabdominal preperitoneal approach (TAPP) has been used to treat inguinal hernias. The patients were divided into two groups: one group underwent laparoscopic surgery using EMARO (E-TAPP) and the other group underwent conventional laparoscopic surgery (L-TAPP). The EMARO is a pneumatically driven endoscope-holder robot. The surgical outcomes of laparoscopic inguinal hernia repair were compared between the two groups.
RESULTS: Fifteen patients underwent E-TAPP, and 36 underwent L-TAPP. The L-TAPP operation requires two personnel, whereas E-TAPP can be performed by one surgeon. The median operation times of the E-TAPP and L-TAPP groups were 81 min (range, 77-87) and 70 min (range, 60-94), respectively, and the median blood loss was 5 mL (range, 1-5) and 2 mL (range, 1-5). However, these differences were not statistically significant. The setup time for EMARO was approximately 8 min (range, 5-12). No patient experienced recurrence, and the postoperative complication rates were similar between the two groups. The number of patients who used postoperative analgesics in the E-TAPP and L-TAPP groups was four (n = 15) and 22 (n = 36), respectively, with a significant difference between the two groups (p = 0.042).
CONCLUSION: Laparoscopic surgery using EMARO can reduce labor costs and postoperative pain. The surgical outcomes of the E-TAPP group were not inferior to those of the L-TAPP group, and E-TAPP could also be safely performed.
FIELD: veterinary science, pharmacology, biology. SUBSTANCE: an antiparasitic preparation comprises avermectin complex including avertin or abamectin, or aversectin C, or ivermectin and others as an antiparasitic agent. The preparation comprises ribav as an immunomodulating agent, ethyl alcohol as a solvent, polyethylene glycol-400 as a chelating agent and perlite as a carrier (adsorbent) being components are taken in the definite ratio. The preparation of proposed composition in oral application provides availability for treatment of animals of any species and enhances their productivity, shows 100% antiparasitic effectiveness and prevents inhibition of immune status. Invention is designated for treatment and prophylaxis of arachnoidal entomosis and nematodosis in domestic and wild animals and birds. EFFECT: enhanced effectiveness of preparation. 3 cl, 3 tbl, 8 ex
For severe cardiac and respiratory failure patients, extra-corporeal membrane oxygenation (ECMO) life support system can help them to have time to wait for the recovery of cardiac and respiratory function or receiving advanced managements. One of the key factors of survival is whether the blood flow supplied by ECMO can meet the need of perfusion of each organ. In our previous study, we found that perfused small vessel density and proportion of perfused small vessel within 18h after placement of venoarterial ECMO (VA-ECMO) were lower in the 28-day non-survivors than those in the survivors. In one research of goal-directed treatment of septic shock, it shows that early microcirculation improved more in the patients with mild organ failure at 24h than in the patients with severe organ failure at 24h. Moreover, in our ongoing observational clinical trial, we found that adjustment of ECMO blood flow could improve microcirculatory dysfunction in some patients. We hypothesize that if we can find out the patients with poor microcirculation and use the microcirculation parameters to assist the adjustment of ECMO blood flow and related treatments, we might improve the survival of these patients. In this clinical trial, the patients will receive microcirculation examination within 18h (T1) after placement of ECMO. The patients were randomly divided into control and microcirculation-assisted groups. The microcirculation parameters in patients of the microcirculation-assisted group will be given to the ECMO team, and the ECMO blood flow and relative treatments will be adjusted according to macrocirculation parameters, clinical condition, and microcirculation parameters. In the patients of the control group, the ECMO blood flow and related treatments will be adjusted according to macrocirculation parameters and clinical condition. The microcirculation will be measured again at 6-22h after T1 and 28-44h after T1, and the ECMO and related treatments will be adjusted as previous description. The microcirculation will be measured at 72h after placement of VA-ECMO. The ECMO setting, intake-output balance, dose of inotropic and vasopressors, and prognosis will be recorded. The difference will be compared between the two groups.
The study protocol in each age group will comprise two visits to the laboratory testing sessions in a randomized order. On one occasion the participants will perform a resting hypoxia test and a graded exercise test to voluntary exhaustion in normoxic condition ((NORM; fraction of inspired oxygen (FiO2)=0.209, placebo). On a second visit the participants will perform a hypoxia sensitivity test and a graded exercise test to voluntary exhaustion in hypoxic condition (HYPO; FiO2=0.120 corresponding to terrestrial altitude of approx. 4000 m). Indirect calorimetry, near infrared spectroscopy and ECG measurements will be performed throughout all tests. During both testing sessions the participants will also undergo anthropometry measurements and pulmonary function testing. The outline of the research visits is presented in the bellow figure:
OBJECTIVES: The current study aimed to examine the incidence of perioperative infections and graft viability in ABO-compatible and ABO-incompatible renal transplant recipients.
METHODS: We included 643 living donor renal transplant recipients registered in the Michinoku Renal Transplant Network from 1998 to 2021. Patients were divided into the ABO-compatible and ABO-incompatible kidney transplantation groups. We compared the characteristics of the two groups and evaluated the incidence of postoperative viral infections (cytomegalovirus and BK virus), graft loss-free survival, and overall survival between the two groups.
RESULTS: Of 643 patients, 485 (75%) and 158 (25%) were ABO-compatible and ABO-incompatible renal transplant recipients, respectively. Postoperative viral infections, rituximab use, and plasma exchange were significantly more common in ABO-incompatible than in ABO-compatible transplant recipients. However, there were no significant differences in terms of other background characteristics. The ABO-incompatible group was more likely to develop viral infections than the ABO-compatible group. Graft loss-free survival and overall survival did not significantly differ between the two groups. According to the multivariate Cox regression analysis, ABO compatibility was not significantly associated with graft loss-free survival and overall survival.
CONCLUSION: Although the incidence of postoperative viral infections in ABO-incompatible renal transplant recipients increased, there was no significant difference in terms of rejection events, graft loss-free survival, and overall survival.
PROBLEM TO BE SOLVED: To obtain a sheeted cosmetic composition having easy handleability and good usability, applicable to the skin and giving the attached area excellent moisture-retention effect, ultraviolet-prevention effect, slimming effect, tightening effect and smoothing effect. SOLUTION: This composition is produced by using a water-soluble nonwoven fabric or woven fabric (especially preferably polyvinyl alcohol fabric). The composition is preferably compounded with humectant, skin-beautifying agent, ultraviolet absorber, slimming agent, blood flow accelerating agent, anti- inflammatory agent, astringent, agent for preventing and improving the formation of wrinkles, chilling agent, thermal agent, etc. A cosmetic composition suitable as a shampooing agent, face-wash, etc., can be produced by compounding the composition with a surfactant as a cleaning agent. The sheeted cosmetic composition has high adhesivity to the skin, is easy-to-peel and washable from the skin after attaching and gives excellent feeling free from stickiness to the skin.  The composition is preferably stored in a package using a gas-barrier material to prevent the deterioration of quality by humidity.
Since the concept of IgG4-related disease (IgG4-RD) was proposed, that diagnosis has been considered in idiopathic fibroinflammatory diseases in various organs, particularly in cases with multi-organ involvement. We have recently encountered three cases of fibrosing disease of uncertain etiology with shared microscopic appearances. Case 1 (56-year-old man) had an irregular mass at the base of mesentery. Case 2 (29-year-old woman) presented with obstructive jaundice due to an ill-defined mass at the hepatic hilum and two lung nodules. Case 3 (53-year-old man) had multiple solid nodules in the mediastinum, peritoneum, retroperitoneum, and mesentery; he also had diffuse irregular narrowing of the intra- and extra-hepatic bile ducts in keeping with sclerosing cholangitis. Serum IgG4 concentrations were not elevated. Biopsies from the nodular lesions showed extensive hyalinizing fibrosis with an only focal lymphoplasmacytic infiltrate. Thick collagenous bundles are arranged in an irregular or partly whorl pattern. Typical storiform fibrosis or obliterative phlebitis was not observed. The number of IgG4-positive plasma cells was <10 cells/high-power field; the ratio of IgG4/IgG-positive plasma cells was <30%. After the histological diagnosis of sclerosing mesenteritis, pulmonary hyalinizing granuloma, and mediastinal fibrosis was made, they were treated with a trial of steroids, but none showed a significant response. In conclusion, a hyalinizing fibrotic condition can occur at various anatomical sites. They have shared microscopic findings, and are steroid-resistant. Although the clinical presentation may mimic IgG4-RD, the two conditions are likely distinct. We would propose a diagnostic term of 'idiopathic hyalinizing fibrosclerosis' for this under-recognized, rare, systemic condition.
PURPOSE: A mutant CTLA4 gene-inserted T cell and a composition containing the same for anticancer immunotherapy are provided to resolve treatment inhibition due to immune tolerance of cancer cells. CONSTITUTION: A fusion protein is prepared by removing an intracellular signal transduction domain of a T-cell surface immune tolerance inducing receptor and fusing an intracellular signal transduction domain of T-cell activation surface protein CD28. The fusion protein is fused by the T-cell surface immune tolerance inducing receptor or a transmembrane domain of CD28. The T-cell surface immune tolerance inducing receptor is CTLA4(cytotoxic t-lymphocyte-associated protein 4, T-lymphocyte antigen 4) or PD1. The fusion protein comprises: an intracellular domain of extracellular domain-CTLA4 transmembrane domain-CD28 of CTLA4; or an intracellular domain of transmembrane domain-CD28 of extracellular domain-CD28. [Reference numerals] (AA) Antigen presenting cell; (BB) Normal T-cell; (CC) CTLA4-induced receptor expression T-cell; (DD) CTLA4-CD28 camera expression T-cell